← Leaderboards
Haidong Dong
Mayo Clinic Rochester
$5,086,281
Attributed
$6,399,231
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $814.3K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,399,231 · 5
By mechanism
R01$6,025,538 · 4
R21$373,693 · 1
Top collaborators
- Eugene D. Kwon6 shared
- Sean S Park3 shared
- Roxana S Dronca2 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Wenqian Hu$5,205,101
- Thomas Patrick Olson$5,622,167
- Daryl J Kor$1,975,293
- Ian J Welsby$1,582,196
- Mostafa Fatemi$15,327,150
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneTumorMalignant NeoplasmsImmunotherapyAntibodiesImmune ResponseCellsT-LymphocyteMediatingTranslatingNeoplastic CellImmunitySignal TransductionAffectCancer PatientIn VivoBlocking AntibodiesResponseTherapeutic EffectOutcome ForecastCancer TherapyReceptorGenerationsDisease Progression
Grant awards (21)
Targeting dual functions of PD-L1 for cancer therapy$363,713
R01 · FY2025 · CA · contact PI
Targeting dual functions of PD-L1 for cancer therapy$345,528
R01 · FY2024 · CA · contact PI
Targeting dual functions of PD-L1 for cancer therapy$356,438
R01 · FY2023 · CA · contact PI
Targeting dual functions of PD-L1 for cancer therapy$356,438
R01 · FY2022 · CA · contact PI
Targeting dual functions of PD-L1 for cancer therapy$363,713
R01 · FY2021 · CA · contact PI
Functional B7-H1 expressed by T cells$397,500
R01 · FY2018 · AI · contact PI
A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR$244,801
R01 · FY2018 · CA
Functional B7-H1 expressed by T cells$397,500
R01 · FY2017 · AI · contact PI
A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR$247,249
R01 · FY2017 · CA
Functional B7-H1 expressed by T cells$397,500
R01 · FY2016 · AI · contact PI
A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR$247,249
R01 · FY2016 · CA
Role of Bim and soluble B7-H1 in monitoring T cell responses to anti-PD-1 therapy in melanoma$169,555
R21 · FY2016 · CA · contact PI
Functional B7-H1 expressed by T cells$397,500
R01 · FY2015 · AI · contact PI
Role of Bim and soluble B7-H1 in monitoring T cell responses to anti-PD-1 therapy in melanoma$204,138
R21 · FY2015 · CA · contact PI
Functional B7-H1 expressed by T cells$397,500
R01 · FY2014 · AI · contact PI
Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma$268,069
R01 · FY2014 · CA
Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma$285,880
R01 · FY2013 · CA
Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma$304,127
R01 · FY2012 · CA
Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma$27,767
R01 · FY2011 · CA
Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma$313,533
R01 · FY2010 · CA
Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma$313,533
R01 · FY2009 · CA